Evidence map›Paper›PMID 42185288›Full record

ArticleNature communications2026

Explainable machine learning-guided integrated multiomics analysis reveals macrophage-driven immune suppression in breast cancer.

Youness Azimzade, Mads Haugland Haugen, Vessela Nedelcheva Kristensen, Arnoldo Frigessi, Alvaro Köhn-Luque

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Youness AzimzadeOslo Center for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway. younessazimzade@gmail.com.ORCID http://orcid.org/0000-0001-7363-7916
Mads Haugland HaugenDepartment of Tumor Biology, Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-7143-2594
Vessela Nedelcheva KristensenDepartment of Medical Genetics, Oslo University Hospital, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0001-5012-7438
Arnoldo FrigessiOslo Center for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway. arnoldo.frigessi@medisin.uio.no.
Alvaro Köhn-LuqueOslo Center for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway. a.k.luque@medisin.uio.no.

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 847912
6 · The paper itself

Abstract

Despite thorough characterizations of cellular compositions within the breast tumor microenvironment (TME), their implications for disease progression and patient prognosis remain poorly understood. Unraveling these effects is vital for identifying potential targets to improve treatment outcomes. In this study, we devise an explainable machine learning (XML) pipeline to scrutinize the associations between TME cellular constituents and relapse-free survival (RFS). By applying this pipeline to estimated cell fractions in the METABRIC and TCGA datasets and comparing these results with associations to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC), we create a comprehensive catalog of the TME's role based on 5000 patient samples. Our findings reveal an unexpected dichotomy in which macrophages correlate positively with pCR but negatively with RFS, particularly within estrogen receptor-positive (ER+) and Luminal A and B (LumA/B) cancer subtypes. We show that this pattern is driven by heterogeneity in breast tumors characterized by increasing levels of macrophage infiltration. Through imaging mass cytometry (IMC) data analysis, we find that macrophages tend to accumulate in the vicinity of HLA-ABC

Indexed as

Breast NeoplasmsMachine LearningMacrophagesFemaleHumansMultiomicsNeoadjuvant TherapyPathologic Complete ResponsePrognosisTumor Microenvironment

Identifiers

PMID42185288
PMCPMC13396660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.